Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children

Marc G. Jeschke, Celeste Finnerty, Gabriela A. Kulp, Rene Przkora, Ronald P. Mlcak, David Herndon

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

OBJECTIVE: Recombinant human growth hormone (rhGH) is a salutary modulator of posttraumatic metabolic responses. However, rhGH administration is associated with deleterious side effects, such as hyperglycemia, increased free fatty acids, and triglycerides, which limit its use. Administration of β-blocker attenuates cardiac work and resting energy expenditure after severe thermal injury and improves fat metabolism and insulin sensitivity. Therefore, the combination of rhGH plus propranolol appears ideal. The aim of the present study was to determine whether rhGH plus propranolol improves hypermetabolism and the inflammatory and acute phase response after severe burn without causing adverse side effects. DESIGN: Prospective randomized control trial. SETTING: Shriners Hospitals for Children. PATIENTS: Fifteen pediatric patients with burns >40% total body surface area, 0.1-16 yrs of age, admitted within 7 days after burn. Fifteen children were matched for burn size, age, gender, inhalation injury, and infection and served as controls. INTERVENTIONS: Patients in the experimental group received rhGH (0.2 mg/kg/day) and propranolol (to decrease heart rate by 15%) for ≥15 days. MEASUREMENTS AND MAIN RESULTS: Outcome measurements included resting energy expenditure, body composition, acute phase proteins, and cytokines. Both cohorts were similar in age, burn size, gender, and accompanying injuries. Percent predicted resting energy expenditure significantly decreased in patients receiving rhGH/propranolol (Δ -5% ± 8%) compared with controls (Δ +35% ± 20%) (p < .05). rhGH/propranolol administration significantly decreased serum C-reactive protein, cortisone, aspartate aminotransferase, alanine aminotransferase, free fatty acids, interleukin-6, interleukin-8, and macrophage inflammatory protein-1β when compared with controls, while growth hormone/propranolol increased serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, growth hormone, prealbumin, and interleukin-7 when compared with placebo (p < .05). CONCLUSIONS: rhGH in combination with propranolol attenuates hypermetabolism and inflammation without the adverse side effects found with rhGH therapy alone.

Original languageEnglish (US)
Pages (from-to)209-216
Number of pages8
JournalPediatric Critical Care Medicine
Volume9
Issue number2
DOIs
StatePublished - Mar 2008

Fingerprint

Human Growth Hormone
Propranolol
Growth Hormone
Inflammation
Energy Metabolism
Nonesterified Fatty Acids
Wounds and Injuries
Macrophage Inflammatory Proteins
Interleukin-7
Insulin-Like Growth Factor Binding Protein 3
Acute-Phase Reaction
Prealbumin
Acute-Phase Proteins
Body Surface Area
Cortisone
Aspartate Aminotransferases
Body Composition
Alanine Transaminase
Interleukin-8
Insulin-Like Growth Factor I

Keywords

  • Anabolic agents
  • Burns
  • Critical care
  • Cytokines
  • Hormones
  • Pediatric

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Critical Care and Intensive Care Medicine

Cite this

Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children. / Jeschke, Marc G.; Finnerty, Celeste; Kulp, Gabriela A.; Przkora, Rene; Mlcak, Ronald P.; Herndon, David.

In: Pediatric Critical Care Medicine, Vol. 9, No. 2, 03.2008, p. 209-216.

Research output: Contribution to journalArticle

Jeschke, Marc G. ; Finnerty, Celeste ; Kulp, Gabriela A. ; Przkora, Rene ; Mlcak, Ronald P. ; Herndon, David. / Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children. In: Pediatric Critical Care Medicine. 2008 ; Vol. 9, No. 2. pp. 209-216.
@article{8b0d7e47d8384c0fb6522d74cf92340d,
title = "Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children",
abstract = "OBJECTIVE: Recombinant human growth hormone (rhGH) is a salutary modulator of posttraumatic metabolic responses. However, rhGH administration is associated with deleterious side effects, such as hyperglycemia, increased free fatty acids, and triglycerides, which limit its use. Administration of β-blocker attenuates cardiac work and resting energy expenditure after severe thermal injury and improves fat metabolism and insulin sensitivity. Therefore, the combination of rhGH plus propranolol appears ideal. The aim of the present study was to determine whether rhGH plus propranolol improves hypermetabolism and the inflammatory and acute phase response after severe burn without causing adverse side effects. DESIGN: Prospective randomized control trial. SETTING: Shriners Hospitals for Children. PATIENTS: Fifteen pediatric patients with burns >40{\%} total body surface area, 0.1-16 yrs of age, admitted within 7 days after burn. Fifteen children were matched for burn size, age, gender, inhalation injury, and infection and served as controls. INTERVENTIONS: Patients in the experimental group received rhGH (0.2 mg/kg/day) and propranolol (to decrease heart rate by 15{\%}) for ≥15 days. MEASUREMENTS AND MAIN RESULTS: Outcome measurements included resting energy expenditure, body composition, acute phase proteins, and cytokines. Both cohorts were similar in age, burn size, gender, and accompanying injuries. Percent predicted resting energy expenditure significantly decreased in patients receiving rhGH/propranolol (Δ -5{\%} ± 8{\%}) compared with controls (Δ +35{\%} ± 20{\%}) (p < .05). rhGH/propranolol administration significantly decreased serum C-reactive protein, cortisone, aspartate aminotransferase, alanine aminotransferase, free fatty acids, interleukin-6, interleukin-8, and macrophage inflammatory protein-1β when compared with controls, while growth hormone/propranolol increased serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, growth hormone, prealbumin, and interleukin-7 when compared with placebo (p < .05). CONCLUSIONS: rhGH in combination with propranolol attenuates hypermetabolism and inflammation without the adverse side effects found with rhGH therapy alone.",
keywords = "Anabolic agents, Burns, Critical care, Cytokines, Hormones, Pediatric",
author = "Jeschke, {Marc G.} and Celeste Finnerty and Kulp, {Gabriela A.} and Rene Przkora and Mlcak, {Ronald P.} and David Herndon",
year = "2008",
month = "3",
doi = "10.1097/PCC.0b013e318166d414",
language = "English (US)",
volume = "9",
pages = "209--216",
journal = "Pediatric Critical Care Medicine",
issn = "1529-7535",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children

AU - Jeschke, Marc G.

AU - Finnerty, Celeste

AU - Kulp, Gabriela A.

AU - Przkora, Rene

AU - Mlcak, Ronald P.

AU - Herndon, David

PY - 2008/3

Y1 - 2008/3

N2 - OBJECTIVE: Recombinant human growth hormone (rhGH) is a salutary modulator of posttraumatic metabolic responses. However, rhGH administration is associated with deleterious side effects, such as hyperglycemia, increased free fatty acids, and triglycerides, which limit its use. Administration of β-blocker attenuates cardiac work and resting energy expenditure after severe thermal injury and improves fat metabolism and insulin sensitivity. Therefore, the combination of rhGH plus propranolol appears ideal. The aim of the present study was to determine whether rhGH plus propranolol improves hypermetabolism and the inflammatory and acute phase response after severe burn without causing adverse side effects. DESIGN: Prospective randomized control trial. SETTING: Shriners Hospitals for Children. PATIENTS: Fifteen pediatric patients with burns >40% total body surface area, 0.1-16 yrs of age, admitted within 7 days after burn. Fifteen children were matched for burn size, age, gender, inhalation injury, and infection and served as controls. INTERVENTIONS: Patients in the experimental group received rhGH (0.2 mg/kg/day) and propranolol (to decrease heart rate by 15%) for ≥15 days. MEASUREMENTS AND MAIN RESULTS: Outcome measurements included resting energy expenditure, body composition, acute phase proteins, and cytokines. Both cohorts were similar in age, burn size, gender, and accompanying injuries. Percent predicted resting energy expenditure significantly decreased in patients receiving rhGH/propranolol (Δ -5% ± 8%) compared with controls (Δ +35% ± 20%) (p < .05). rhGH/propranolol administration significantly decreased serum C-reactive protein, cortisone, aspartate aminotransferase, alanine aminotransferase, free fatty acids, interleukin-6, interleukin-8, and macrophage inflammatory protein-1β when compared with controls, while growth hormone/propranolol increased serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, growth hormone, prealbumin, and interleukin-7 when compared with placebo (p < .05). CONCLUSIONS: rhGH in combination with propranolol attenuates hypermetabolism and inflammation without the adverse side effects found with rhGH therapy alone.

AB - OBJECTIVE: Recombinant human growth hormone (rhGH) is a salutary modulator of posttraumatic metabolic responses. However, rhGH administration is associated with deleterious side effects, such as hyperglycemia, increased free fatty acids, and triglycerides, which limit its use. Administration of β-blocker attenuates cardiac work and resting energy expenditure after severe thermal injury and improves fat metabolism and insulin sensitivity. Therefore, the combination of rhGH plus propranolol appears ideal. The aim of the present study was to determine whether rhGH plus propranolol improves hypermetabolism and the inflammatory and acute phase response after severe burn without causing adverse side effects. DESIGN: Prospective randomized control trial. SETTING: Shriners Hospitals for Children. PATIENTS: Fifteen pediatric patients with burns >40% total body surface area, 0.1-16 yrs of age, admitted within 7 days after burn. Fifteen children were matched for burn size, age, gender, inhalation injury, and infection and served as controls. INTERVENTIONS: Patients in the experimental group received rhGH (0.2 mg/kg/day) and propranolol (to decrease heart rate by 15%) for ≥15 days. MEASUREMENTS AND MAIN RESULTS: Outcome measurements included resting energy expenditure, body composition, acute phase proteins, and cytokines. Both cohorts were similar in age, burn size, gender, and accompanying injuries. Percent predicted resting energy expenditure significantly decreased in patients receiving rhGH/propranolol (Δ -5% ± 8%) compared with controls (Δ +35% ± 20%) (p < .05). rhGH/propranolol administration significantly decreased serum C-reactive protein, cortisone, aspartate aminotransferase, alanine aminotransferase, free fatty acids, interleukin-6, interleukin-8, and macrophage inflammatory protein-1β when compared with controls, while growth hormone/propranolol increased serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, growth hormone, prealbumin, and interleukin-7 when compared with placebo (p < .05). CONCLUSIONS: rhGH in combination with propranolol attenuates hypermetabolism and inflammation without the adverse side effects found with rhGH therapy alone.

KW - Anabolic agents

KW - Burns

KW - Critical care

KW - Cytokines

KW - Hormones

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=40449113475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449113475&partnerID=8YFLogxK

U2 - 10.1097/PCC.0b013e318166d414

DO - 10.1097/PCC.0b013e318166d414

M3 - Article

C2 - 18477935

AN - SCOPUS:40449113475

VL - 9

SP - 209

EP - 216

JO - Pediatric Critical Care Medicine

JF - Pediatric Critical Care Medicine

SN - 1529-7535

IS - 2

ER -